- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
This study, called ENERGY, is looking at a new medicine called INZ-701 for babies with certain rare genetic conditions. Doctors want to see if the medicine is safe, how it's handled by the body, and if it helps by checking things like blood and heart health.
For: Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) DeficiencySpain - Active not recruitingPHASE3
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
The ENERGY 3 Study is looking at a new treatment called INZ-701 for children aged 1-12 with a rare genetic condition called ENPP1 Deficiency. This study wants to see how well INZ-701 works and if it's safe compared to usual care.
For: Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency · Autosomal Recessive Hypophosphatemic Rickets · Generalized Arterial Calcification of InfancyUnited States · Australia · Canada - RecruitingPHASE3
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
This study, called ENERGY 2, is looking at a new medicine called INZ-701 for babies with a rare genetic condition called ENPP1 Deficiency. Researchers want to see if the medicine is safe and helps improve the health of these babies.
For: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency · Autosomal Recessive Hypophosphatemic Rickets · Generalized Arterial Calcification of Infancy 1Brazil · France · Hungary - RecruitingPHASE1
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
The ENERGY Study is looking into a new medicine called INZ-701 for babies under one year old with two rare genetic conditions: ENPP1 Deficiency or ABCC6 Deficiency. The main goal is to check how safe the medicine is and if babies can tolerate it well.
For: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency · Autosomal Recessive Hypophosphatemic Rickets · Generalized Arterial Calcification of InfancyUnited States · Spain · United Kingdom - RecruitingPHASE2
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
This study looks at the long-term safety of a treatment called INZ-701 for people with rare conditions like ENPP1 Deficiency or ABCC6 Deficiency. It's for patients who have already tried INZ-701 in a previous study and wish to continue.
For: Gene Mutations · Pseudoxanthoma Elasticum · Arterial CalcificationUnited States · France · Germany